Welcome to the National Non-Hodgkin Lymphoma Audit (NNHLA).
More than 14,000 people are diagnosed with Non-Hodgkin Lymphoma in the UK every year, and the audit will analyse data looking into their diagnosis and treatment in detail. The aim is to feed results back to individual cancer services and hospitals, as well as to the NHS at a national level in England and Wales.
Timely results will be published every three or four months in order to produce continuous improvement for patients diagnosed with Non-Hodgkin Lymphoma.
It can be a difficult cancer to study – there are more than 200 types of lymphoma. But one of the clinical co-leads on the audit, Cathy Burton, says the aim is to focus not just on the most common lymphomas but also on rarer ones like T-cell lymphomas, which are difficult to diagnose and treat. You can hear more of her thoughts here:
Cathy Burton, Clinical Lead (Haematology), National Non-Hodgkin Lymphoma Audit
As well as clinical experts, charities will be well represented in the audit process to make sure the voices of patients and the public are heard.
One of the main objectives of the audit will be to focus on equity. It’s really important to work towards a service where all patients are given access to the appropriate diagnostic procedures and treatments.
Rincy George, Policy Officer, Blood Cancer UK
Tara Steed, Policy and Public Affairs Advisor, Lymphoma Action
One of the first tasks of the audit will be to establish which questions are the right ones to focus on. Together with our stakeholders we are identifying an initial set of key performance indicators which will be subject to ongoing development and validation.
The clinical leads for NNHLA, who will help guide this process, are as follows:
- Dr Cathy Burton, Clinical Lead (Haematology), representing the British Society of Haematology (BSH).
- Dr David Cutter, Clinical Lead (Oncology), representing the Royal College of Radiologists (RCR).
This page will be updated whenever more information becomes available. The first results of the audit will start to become available next year, and we intend to keep everyone informed as fully as possible.
Want to find out more? Reach out to us via email.
Email: [email protected]